natgillin/translations-raw huggingface dataset:
In vitro, the binding of cabazitaxel to human serum proteins was 89-92% and was not saturable up to 50,000 ng/ml, which covers the maximum concentration observed in clinical studies. 
In vitro je bila vezava kabazitaksela na beljakovine v človeškem serumu 82-92 % in ni bila saturabilna do 50.000 ng/ml; to vključuje največjo koncentracijo, ugotovljeno v kliničnih študijah.
Therefore the risk of interaction with substrates of MRP, OCT1, PgP, BCRP and OATP1B3 is unlikely in vivo at the dose of 25 mg/m2. 
Zato tveganje medsebojnega delovanja s substrati MRP, OCT1, PgP, BCRP in OATP1B3 in vivo pri odmerku 25 mg/m2 ni verjetno.
Severe reactions can occur and may include generalised rash/erythema, hypotension and bronchospasm. 
Pojavijo se lahko hude reakcije, med njimi generaliziran izpuščaj/eritem, hipotenzija in bronhospazem.
Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents may result in serious or fatal infections. 
Uporaba živih ali živih oslabljenih cepiv pri bolnikih, ki so imunsko oslabeli zaradi kemoterapije, lahko povzroči resne okužbe ali okužbe s smrtnim izidom.
Due to potential effects on male gametes and to potential exposure via seminal liquid, men treated with cabazitaxel should use effective contraception throughout treatment and are recommended to continue this for up to 6 months after the last dose of cabazitaxel. 
Zaradi možnih učinkov na moške gamete in možno izpostavljenost preko semenske tekočine morajo moški, zdravljeni s kabazitakselom, uporabljati učinkovito kontracepcijo med celotnim zdravljenjem; priporočljivo je, da jo uporabljajo tudi še 6 mesecev po zadnjem odmerku kabazitaksela.
INFORMATION IN BRAILLE Justification for not including Braille accepted. 
PODATKI V BRAILLOVI PISAVI Sprejeta je utemeljitev, zakaj niso vključeni podatki v Braillovi pisavi.
If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hour at 2°C - 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Če ni uporabljena takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika; čas običajno ne sme presegati 24 ur na temperaturi od 2°C do 8°C, razen če je redčenje opravljeno v nadzorovanih in preverjenih aseptičnih pogojih.
It was not clastogenic in an in vitro test in human lymphocytes (no induction of structural chromosomal aberration but it increased number of polyploid cells) and induced an increase of micronuclei in the in vivo test in rats. 
V testu na človeških limfocitih in vitro ni bil klastogen (ni induciral strukturnih kromosomskih aberacij, povečal pa je število poliploidnih celic) ter je izzval povečanje mikrojeder v testih in vivo na podganah.
It works by stopping cells from growing and multiplying. 
Deluje tako, da prepreči rast in razmnoževanje celic.
As with other cytotoxic medicinal products, cabazitaxel may cause foetal harm in exposed pregnant women. 
Tako kot druga citotoksična zdravila lahko tudi kabazitaksel škoduje plodu izpostavljene nosečnice.
Caution is recommended in patients with haemoglobin <10 g/dl and appropriate measures should be taken as clinically indicated. 
Pri bolnikih, ki imajo hemoglobin < 10 g/dl, je potrebna previdnost in treba je ustrezno ukrepati, kot je klinično indicirano.
One pack of JEVTANA contains: 
Eno pakiranje zdravila JEVTANA vsebuje:
The safety and the efficacy of JEVTANA in children and adolescents below 18 years of age have not been established (see section 5.1). 
Varnost in učinkovitost zdravila JEVTANA pri otrocih in mladostnikih do 18 let nista bili dokazani (glejte poglavje 5.1).
These patients received cabazitaxel at doses of 10 to 30 mg/m2 weekly or every 3 weeks. 
Ti bolniki so prejemali kabazitaksel v odmerkih od 10 do 30 mg/m2 na teden ali na 3 tedne.
Serum creatinine should be measured at baseline, with each blood count and whenever the patient reports a change in urinary output. 
Kreatinin v serumu je treba izmeriti na začetku, pri vsaki določitvi krvne slike in kadarkoli bolnik navede spremembo v količini izločenega urina.
Information about storage and the time to use JEVTANA, once it has been diluted and is ready to use, are described in the section “PRACTICAL INFORMATION FOR MEDICAL OR HEALTHCARE PROFESSIONALS ON PREPARATION, ADMINISTRATION AND HANDLING OF JEVTANA“. 
Informacije o shranjevanju in času za uporabo zdravila JEVTANA, ko je že redčeno in pripravljeno za uporabo, so navedene v poglavju "PRAKTIČNE INFORMACIJE ZA ZDRAVSTVENO OSEBJE O PRIPRAVI, UPORABI IN RAVNANJU Z ZDRAVILOM JEVTANA ".
Renal failure including cases with fatal outcome has been observed. 
Zabeležena je bila odpoved ledvic, tudi s smrtnim izidom.
Since foam may persist on the wall of the vial of this solution, following its preparation described in Step 1, it is preferable to place the needle of the syringe in the middle when extracting. 
Ker je lahko po pripravi, opisani v koraku 1, na steni viale z raztopino prisotna pena, je bolje, da pri izvleku namestite iglo brizge na sredino.
In this case, the solution must not be used and should be discarded. 
V takšnem primeru raztopine ne smete uporabiti, ampak jo morate zavreči.
Cabazitaxel treatment delay or discontinuation may be necessary. 
Potrebna je lahko odložitev ali prekinitev zdravljenja s kabazitakselom.
Concentrate vial (60 mg - 1.5 ml) 
Viala s koncentratom (60 mg - 1.5 ml)
• corticosteroid (dexamethasone 8 mg or equivalent), and 
• kortikosteroid (8 mg deksametazona ali enakovredno zdravilo) in
JEVTANA is used to treat prostate cancer that has progressed after having had other chemotherapy. 
Zdravilo JEVTANA se uporablja za zdravljenje raka prostate, ki je napredoval po zdravljenju z drugo kemoterapijo.
• fever (high temperature). 
• zvišano telesno temperaturo (vročino).
To limit foaming as much as possible when injecting the solvent, direct the needle onto the inside wall of the vial of concentrate solution and inject slowly. 
Da bo med brizganjem vehikla čim manj penjenja, usmerite iglo v notranjo steno viale z raztopino koncentrata in injicirajte počasi.
Appropriate measures should be taken to identify the cause and intensively treat the patients if this occurs. 
Če se to zgodi, so potrebni ustrezni ukrepi za ugotovitev vzroka in intenzivno zdravljenje bolnikov.
• H2 antagonist (ranitidine or equivalent) (see section 4.4). 
• antagonist H2 (ranitidin ali enakovredno zdravilo) (glejte poglavje 4.4).
1.5 ml 10 mg/ml after first dilution. 
1,5 ml 10 mg/ml po prvem redčenju.
After a 1-hour intravenous infusion [14C]-cabazitaxel at 25 mg/m2 in patients, approximately 80% of the administered dose was eliminated within 2 weeks. 
Po 1-urni intravenski infuziji [14C]-kabazitaksela v odmerku 25 mg/m2 pri bolnikih se je približno 80 % uporabljenega odmerka odstranilo v 2 tednih.
Before each treatment with JEVTANA, you will have blood tests to check that you have enough blood cells and sufficient liver and kidney functions to receive JEVTANA. 
Pred vsakim zdravljenjem z zdravilom JEVTANA boste morali opraviti preiskave krvi, s katerimi bo zdravnik preveril, ali imate dovolj krvnih celic ter zadostno delovanje jeter in ledvic, da lahko dobite zdravilo JEVTANA.
One patient in the cabazitaxel group died from cardiac failure. 
En bolnik v skupini s kabazitakselom je umrl zaradi srčnega popuščanja.
Fatal ventricular fibrillation was reported in 1 patient (0.3%), and cardiac arrest in 2 patients (0.5%). 
Fibrilacija prekatov s smrtnim izidom je bila opisana pri 1 bolniku (0,3 %) in zastoj srca pri 2 bolnikih (0,5 %).
If the treatment is envisaged in patients with moderate hepatic impairment the dose of cabazitaxel should not exceed 15 mg/m2. 
Če je predvideno zdravljenje pri bolnikih z zmerno okvaro jeter, odmerek kabazitaksela ne sme preseči 15 mg/m2.
• severe stomach pain or stomach pain that doesn't go away. 
• hude bolečine v trebuhu ali bolečine v trebuhu, ki ne minejo.
The risk of interaction with OATP1B1 transporter is possible, notably during the infusion duration (1 hour) and up to 20 minutes after the end of the infusion (see section 4.5). 
Tveganje medsebojnega delovanja s prenašalcem OATP1B1 je možno, predvsem v času trajanja infuzije (1 uro) in do 20 minut po koncu infuzije (glejte poglavje 4.5).
One pack contains one vial of concentrate and one vial of solvent: 
Eno pakiranje vsebuje eno vialo koncentrata in eno vialo vehikla:
Concomitant medicinal products that are strong inducers or strong inhibitors of CYP3A should be avoided. 
Potrebno se je izogibati sočasni uporabi drugih zdravil, ki so močni induktorji ali močni zaviralci CYP3A.
SPECIAL STORAGE CONDITIONS Do not store above 30°C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Ne shranjujte pri temperaturi nad 30°C.
The incidence of atrial fibrillation was 1.1% in the cabazitaxel group. 
Incidenca atrijske fibrilacije je bila v skupini s kabazitakselom 1,1 %.
The most common adverse reactions leading to cabazitaxel discontinuation was neutropenia. 
Najpogostejši neželeni učinek, ki je povzročil prenehanje uporabe kabazitaksela, je bila nevtropenija.
If you are not sure, talk to your doctor before having JEVTANA. 
Če ste negotovi, se posvetujte z zdravnikom, preden dobite zdravilo JEVTANA.
• As part of your treatment, you will also take a corticosteroid medicine (prednisone or prednisolone) by mouth every day. 
• Kot del zdravljenja boste vsak dan zaužili tudi kortikosteroidno zdravilo (prednizon ali prednizolon).
Symptoms such as abdominal pain and tenderness, fever, persistent constipation, diarrhoea, with or without neutropenia, may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly. 
Simptomi, kot so bolečine v trebuhu ali občutljivost trebuha, zvišana telesna temperatura, dolgotrajna zaprtost, driska, z nevtropenijo ali brez nje, so lahko zgodnji znaki resnih toksičnih učinkov na prebavilih in jih je treba takoj ovrednotiti in zdraviti.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturers responsible for batch release 
A. IZDELOVALCI , ODGOVORNI ZA SPROŠČANJE SERIJ Ime in naslov izdelovalcev, odgovornih za sproščanje serij
Cabazitaxel did not inhibit in vitro the major biotransformation pathway of warfarin into 7-hydroxywarfarin, which is mediated by CYP2C9. 
Kabazitaksel in vitro ni zavrl glavne poti biotransformacije varfarina v 7-hidroksivarfarin, ki poteka preko CYP2C9.
Among the 371 patients treated with cabazitaxel in the prostate cancer study, 240 patients were 65 years or over including 70 patients older than 75 years. 
Med 371 bolniki, ki so prejemali kabazitaksel v študiji raka prostate, je bilo 240 bolnikov starih 65 let ali več, med njimi 70 bolnikov, starejših od 75 let.
To be taken into account if you are in a high-risk group such as patients with liver disease, or epilepsy. 
To je treba upoštevati, če spadate v skupino z velikim tveganjem, kakršna so bolniki z boleznijo jeter ali z epilepsijo.
If patients experience nausea or vomiting, they may be treated with commonly used anti-emetics. 
Če se bolnikom pojavita navzea ali bruhanje, ju je mogoče zdraviti z običajno uporabljanimi antiemetiki.
Table 3 - Efficacy of JEVTANA in EFC6193 study in the treatment of patients with metastatic castration resistant prostate cancer 
Preglednica 3 - Učinkovitost zdravila JEVTANA v študiji EFC6193 pri zdravljenju bolnikov z metastatskim, na kastracijo odpornim rakom prostate
• urinary incontinence 
• inkontinenca urina
Seven metabolites were detected in plasma (including 3 active metabolites issued form O-demethylations), with the main one accounting for 5% of parent exposure. 
V plazmi so ugotovili sedem presnovkov (vključno s 3 aktivnimi presnovki O-demetilacije); glavni od njih doseže 5 % izpostavljenosti matičnemu zdravilu.
Cabazitaxel is mainly bound to human serum albumin (82.0%) and lipoproteins (87.9% for HDL, 69.8% for LDL, and 55.8% for VLDL). 
Kabazitaksel je v glavnem vezan na človeški serumski albumin (82,0 %) in na lipoproteine (87,9 % pri HDL, 69,8 % pri LDL in 55,8 % pri VLDL).
What JEVTANA is and what it is used for 
Kaj je zdravilo JEVTANA in za kaj ga uporabljamo
Intensity of the adverse reactions is graded according to CTCAE 4.0 (grade ≥3 = G≥3). 
Izrazitost neželenih učinkov je ocenjena po skupnih merilih toksičnosti CTCAE 4.0 (stopnja ≥ 3 = S ≥ 3).
Secondary endpoints included Progression Free Survival [PFS (defined as time from randomization to tumour progression, Prostatic Specific Antigen (PSA) progression, pain progression, or death due to any cause, whichever occurred first], Tumour Response Rate based on Response Evaluation Criteria in Solid Tumours (RECIST), PSA Progression (defined as a ≥25% increase or >50% in PSA non-responders or responders respectively), PSA response (declines in serum PSA levels of at least 50%), pain progression [assessed using the Present Pain Intensity (PPI) scale from the McGill-Melzack questionnaire and an Analgesic Score (AS)] and pain response (defined as 2-point greater reduction from baseline median PPI with no concomitant increase in AS, or reduction of ≥50% in analgesic use from baseline mean AS with no concomitant increase in pain). 
Sekundarni opazovani dogodki so vključevali preživetje brez napredovanja [PBN (opredeljeno kot čas od randomizacije do napredovanja tumorja, napredovanja prostatično specifičnega antigena (PSA), napredovanja bolečin ali smrti zaradi kateregakoli razloga, kar od tega se je zgodilo najprej], delež odziva tumorja na podlagi meril RECIST (Response Evaluation Criteria in Solid Tumours), napredovanje PSA (opredeljeno kot ≥ 25 % porast PSA pri neodzivnih oz. > 50 % porast PSA pri odzivnih), odziv PSA (zmanjšanje koncentracije PSA v serumu za vsaj 50 %), napredovanje bolečin [ocenjeno z lestvico PPI (Present Pain Intensity) iz McGill-Melzackovega vprašalnika in s točkovno oceno AS (Analgesic Score) in odziv bolečin (opredeljen kot 2-točki večje zmanjšanje izhodiščnega medianega PPI brez sočasnega povečanja AS ali kot ≥ 50 % zmanjšanje uporabe analgetika od izhodiščne povprečne AS brez hkratnega povečanja bolečin).
Colitis, enterocolitis, gastritis, neutropenic enterocolitis have been observed. 
Opažali so kolitis, enterokolitis, gastritis in nevtropenični enterokolitis.
Cabazitaxel demonstrated a broad spectrum of antitumour activity against advanced human tumours xenografted in mice. 
Kabazitaksel je pokazal širok spekter protitumorskega delovanja proti napredovalim človeškim tumorjem, presajenim mišim.
Harmful for those suffering from alcoholism. 
To je škodljivo za osebe, ki imajo težave s prekomernim uživanjem alkohola.
Number of deaths, n (%) Median survival (95% CI) (months) 
Celokupno preživetje Število smrti, n (%) Mediano preživetje (95 % IZ) (meseci)
Its common name is cabazitaxel. 
Njegovo splošno ime je kabazitaksel.
• you have any bleeding problems from the gut or have changes in the colour of your stool or stomach pain. 
• imate krvavitev iz črevesa ali spremenjeno barvo blata ali bolečine v želodcu.
The incidence of grade ≥3 anaemia, increased AST, ALT, and bilirubin based on laboratory abnormalities were 10.5%, 0.7%, 0.9%, and 0.6%, respectively. 
Incidence anemije, zvišanja AST, ALT in bilirubina ≥ 3. stopnje je bila na podlagi laboratorijskih nepravilnosti so bile 10,5 %, 0,7 %, 0,9 % in 0,6 %.
Patients received a median duration of 6 cycles of cabazitaxel. 
Bolniki so mediano prejeli 6 ciklusov kabazitaksela.
This study included patients over 18 years of age with metastatic castration resistant prostate cancer either measurable by RECIST criteria or non-measurable disease with rising PSA levels or appearance of new lesions, and Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. 
Ta študija je vključila bolnike, starejše od 18 let z metastatskim, na kastracijo odpornim rakom prostate, z merljivo boleznijo po merilih RECIST ali z nemerljivo boleznijo, z naraščanjem koncentracije PSA ali pojavom novih lezij in s stanjem zmogljivosti od 0 do 2 po ECOG (Eastern Cooperative Oncology Group).
Serious allergic reactions can occur during treatment with JEVTANA. 
Med zdravljenjem z zdravilom JEVTANA se lahko pojavijo resne alergijske reakcije.
Premedication The recommended premedication regimen should be performed at least 30 minutes prior to each administration of JEVTANA with the following intravenous medicinal products to mitigate the risk and severity of hypersensitivity: 
Premedikacija Priporočeno shemo premedikacije naj bi se začelo izvajati vsaj 30 minut pred vsako uporabo zdravila JEVTANA, in sicer z naslednjimi intravenskimi zdravili, da bi zmanjšali tveganje in izrazitost preobčutljivosti:
Safety and effectiveness of JEVTANA have not been established in children and adolescents below 18 years of age. 
Pediatrični bolniki Varnost in učinkovitost zdravila JEVTANA pri otrocih in mladostnikih do 18 let nista ugotovljeni.
People with low blood counts can develop life-threatening infections. 
Osebam z majhnim številom krvnih celic se lahko pojavijo smrtno nevarne okužbe.
Results of environmental risk assessment studies indicated that use of JEVTANA will not cause significant risk to the aquatic environment (see section 6.6 for disposal of unused product). 
Ocena okoljskega tveganja (ERA - Environmental Risk Assessment) Rezultati študij ocene okoljskega tveganja kažejo, da uporaba zdravila JEVTANA ne povzroča pomembnega tveganja za vodno okolje (glejte poglavje 6.6 za odlaganje neporabljenega zdravila).
Primary prophylaxis with G-CSF should be considered in patients with high-risk clinical features (age >65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities) that predispose them to increased complications from prolonged neutropenia. 
O primarni profilaksi z G-CSF je treba razmisliti pri bolnikih z velikim kliničnim tveganjem (starost > 65 let, slabo stanje zmogljivosti, predhodna obdobja febrilne nevtropenije, obsežna predhodna obsevanja, slabo prehransko stanje ali druga resna komorbidna stanja), ki imajo večje nagnjenje k zapletom dolgotrajne nevtropenije.
A population pharmacokinetic analysis was carried out in 170 patients including patients with advanced solid tumours (n=69), metastatic breast cancer (n=34) and metastatic prostate cancer (n=67). 
Analiza populacijske farmakokinetike je bila opravljena pri 170 bolnikih, vključno z bolniki z napredovalimi parenhimskimi tumorji (n = 69), metastatskim rakom dojke (n = 34) in metastatskim rakom prostate (n = 67).
There was no significant difference in overall survival in this group of patients (HR (95%CI) 0.96 (0.49-1.86)). 
V omenjeni skupini ni bilo značilne razlike v celotnem preživetju (ROg (95% IZ) 0,96 (0,49-1,86))
Severe hypersensitivity reactions require immediate discontinuation of cabazitaxel and appropriate therapy. 
Hude preobčutljivostne reakcije zahtevajo takojšnjo prekinitev dajanja kabazitaksela in ustrezno zdravljenje.
There was no statistical difference between both treatment arms in pain progression and pain response. 
Terapevtska kraka se nista statistično značilno razlikovala glede napredovanja bolečin in odziva bolečin.
After final dilution in the infusion bag/bottle 
Po končnem redčenju v vrečki/steklenici za infundiranje:
Elderly people (≥65 years of age) may be more likely to experience certain adverse reactions including neutropenia and febrile neutropenia (see section 4.8). 
Pri starejših bolnikih (starih ≥ 65 let) lahko obstaja večja verjetnost določenih neželenih učinkov, vključno z nevtropenijo in febrilno nevtropenijo (glejte poglavje 4.8).
As part of your treatment, you will also take a corticosteroid medicine (prednisone or prednisolone) by mouth every day. 
Kot del zdravljenja boste vsak dan zaužili tudi kortikosteroidno zdravilo (prednizon ali prednizolon).
To be taken into account in high-risk groups such as patients with liver disease, or epilepsy. 
To je treba upoštevati v skupinah z velikim tveganjem, npr. pri bolnikih z boleznijo jeter ali z epilepsijo.
Facilities and equipment for the treatment of serious hypersensitivity reactions like hypotension and bronchospasm must be available (see section 4.4). 
Na voljo morajo biti prostor in oprema za zdravljenje resnih preobčutljivostnih reakcij, npr. hipotenzije in bronhospazma (glejte poglavje 4.4).
Interruption of cabazitaxel therapy is recommended until diagnosis is available. 
Priporočljiva je prekinitev zdravljenja s kabazitakselom, dokler ni postavljena diagnoza.
For instructions on preparation and administration of the product, see section 6.6. 
Za navodila za pripravo in dajanje zdravila glejte poglavje 6.6.
In rats, cabazitaxel and its metabolites are excreted in maternal milk at a quantity up to 1.5% of administered dose over 24 hours. 
Pri podganah se kabazitaksel in njegovi presnovki izločijo v materinem mleku v količini do 1,5 % uporabljenega odmerka v 24 urah.
However a clinical study has shown that cabazitaxel (25 mg/m2 administered as a single 1-hour infusion) did not modify the plasma levels of midazolam, a probe substrate of CYP3A. 
Vendar je klinična študija pokazala, da kabazitaksel (25 mg/m2 v eni sami 1-urni infuziji) ni spremenil plazemske koncentracije midazolama, ki je testni substrat CYP3A.
Neutropenic complications included neutropenic infections (0.5%), neutropenic sepsis (0.8%), and septic shock (1.1%), which in some cases resulted in a fatal outcome. 
Med nevtropeničnimi zapleti so bile nevtropenične okužbe (0,5 %), nevtropenična sepsa (0,8 %) in septični šok (1,1 %), v nekaterih primerih s smrtnim izidom.
Cabazitaxel binds to tubulin and promotes the assembly of tubulin into microtubules while simultaneously inhibiting their disassembly. 
Kabazitaksel se veže na tubulin in pospešuje združevanje tubulina v mikrotubule, hkrati pa zavre njihovo razgrajevanje.
You may feel tired or dizzy when having this medicine. 
Med zdravljenjem s tem zdravilom se vam lahko pojavi utrujenost ali omotica.
OTHER This vial contains an overfill. 
DRUGI PODATKI Viala vsebuje prepolnitev.
• sore in the mouth or on lips 
• razjeda v ustih ali na ustnicah
Cabazitaxel is minimally excreted via the kidney (2.3% of the dose). 
Kabazitaksel se le minimalno izloča skozi ledvice (2,3 % odmerka).
As with all parenteral products, the resulting infusion solution should be visually inspected prior to use. 
Tako kot vsa zdravila za parenteralno uporabo je treba nastalo raztopino za infundiranje pred uporabo pregledati.
Decreased appetite Vomiting 
Zmanjšan apetit
Remove the syringe and needle and mix manually and gently by repeated inversions until obtaining a clear and homogeneous solution. 
Odstranite brizgo in iglo in previdno ročno premešajte tako, da vialo večkrat obrnete, dokler ne dobite bistre in homogene raztopine.
The anticipated complications of overdose would consist of exacerbation of adverse reactions as bone marrow suppression and gastrointestinal disorders. 
Predvideni zapleti prevelikega odmerjanja bi obsegali poslabšanje neželenih učinkov, npr. supresije kostnega mozga in gastrointestinalnih težav.
In vitro cabazitaxel did not inhibit Multidrug-Resistant Proteins (MRP): MRP1 and MRP2 or Organic Cation Transporter (OCT1). 
In vitro kabazitaksel ni zavrl proti več zdravilom odpornih beljakovin (MRP) MRP1 in MRP2 ali prenašalcev organskih kationov (OCT1).
• rapid or irregular heartbeat 
• hitro ali neredno bitje srca
Excipient with known effect Each vial of solvent contains 573.3 mg of ethanol 96%. 
Pomožna snov z znanim učinkom Ena viala vehikla vsebuje 573,3 mg 96 % etanola.
The risk of interaction with OATP1B1 substrates (e.g. statins, valsartan, repaglinide) is possible, notably during the infusion duration (1 hour) and up to 20 minutes after the end of the infusion. 
Tveganje medsebojnega delovanja s substrati OATP1B1 (npr. statini, valsartan, repaglinid) je možno predvsem v času trajanja infuzije (1 uro) in do 20 minut po koncu infuzije.
• JEVTANA must be prepared (diluted) before it is given. 
• Zdravilo JEVTANA je treba pred dajanjem pripraviti (redčiti).
Incidence of grade ≥3 neutropenia based on laboratory data was 81.7%. 
Na podlagi laboratorijskih podatkov je bila incidenca nevtropenije ≥ 3. stopnje 81,7 %.